20:34 , Jul 21, 2017 |  BC Week In Review  |  Financial News

Trevi raises $50.5M in series C

On July 20, dermatology play Trevi Therapeutics Inc. (New Haven, Conn.) raised $50.5 million in a series C round led by New Enterprise Associates . New investors Lundbeckfonden Ventures, Omega Funds, and Aperture Venture Partners...
17:12 , Jul 21, 2017 |  BioCentury  |  Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20...
23:16 , Jul 20, 2017 |  BC Extra  |  Financial News

NEA leads Trevi's $50.5M series C round

Dermatology play Trevi Therapeutics Inc. (New Haven, Conn.) raised $50.5 million in a series C round led by New Enterprise Associates . New investors Lundbeckfonden Ventures, Omega Funds, and Aperture Venture Partners also participated, as...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
19:57 , Mar 10, 2017 |  BC Week In Review  |  Financial News

Biohaven Pharmaceuticals completes venture financing

On March 7, neurology company Biohaven Pharmaceutical Holding Co. Ltd. (New Haven, Conn.) raised $40 million in the second tranche of a series A round led by Venrock, bringing the total raised to $80 million....
02:08 , Nov 5, 2016 |  BioCentury  |  Finance

Craving Biohaven

Biohaven Pharmaceutical Holding Co. Ltd. raised a tranched $80 million private round on its management team’s track record of bringing neurology compounds through the clinic, and the range of both Orphan and common indications the...
20:38 , Nov 4, 2016 |  BC Week In Review  |  Financial News

Biohaven completes venture financing

Biohaven raised $80 million in a private financing led by Venrock. RA Capital Management, Vivo Capital, Aisling Capital , Rock Springs Capital, John W. Childs, Knoll Capital Management, Osage University Partners, Aperture Venture Partners, Connecticut...
23:13 , Nov 1, 2016 |  BC Extra  |  Financial News

Biohaven raises $80M round

Neurology company Biohaven Pharmaceutical Holding Co. Ltd. (Tortola, Virgin Islands) raised $80 million in an oversubscribed private round led by Venrock. Other participants included RA Capital, Vivo Capital, Aisling Capital , Rock Springs Capital, John...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Financial News

Aclaris completes venture financing

Aclaris Therapeutics Inc. , Malvern, Pa.   Business: Dermatology   Date completed: 2015-09-09   Type: Venture financing   Raised: $40 million   Investors: RA Capital Management; Cormorant Asset Management; Rock Springs Capital; Aperture Venture Partners;...
01:19 , Sep 10, 2015 |  BC Extra  |  Financial News

Aclaris raises $40M, licenses Rigel's JAK inhibitors

Aclaris Therapeutics Inc. (Malvern, Pa.) raised $40 million in series C funding led by RA Capital; Cormorant Asset Management; Rock Springs Capital; Aperture Venture Partners; and Mossrock Capital. Existing investors Vivo Capital; Fidelity Biosciences; and...